The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Prostate artery embolisation for benign prostatic hyperplasia [IPG453] in April 2013. NICE is currently updating this guidance. The new guidance will be published shortly. Until then the NHS should continue to follow the recommendations outlined in the current version of the guidance. The Interventional Procedures Advisory Committee (IPAC) will consider this procedure review and NICE will issue an interventional procedures consultation document about its safety and efficacy for 4 weeks’ public consultation. IPAC will then review the consultation document in the light of comments received and produce a final interventional procedures document, which will be considered by NICE before guidance is issued to the NHS in England, Wales, Scotland and Northern Ireland.
Status In progress
Process IP
Description Prostate artery embolisation for benign prostate hyperplasia is usually done using local anaesthesia and conscious sedation. The prostate is approached through the left or right femoral artery. Super-selective catheterisation of the small prostatic arteries is done using fine microcatheters through the internal iliac and vesical arteries. Embolisation involves the introduction of microparticles to completely block the prostatic vessels. Embolisation agents include polyvinyl alcohol (PVA), gelfoam sponge and other newer synthetic biocompatible materials. The aim of prostate artery embolisation is to starve the prostate gland of its blood supply, causing some of it to undergo necrosis with subsequent shrinkage. The potential benefits of prostate artery embolisation over surgery include a reduction in morbidity and avoiding a general anaesthetic.

For further information on how we develop guidance, please see our page about NICE interventional procedures guidance